Cover Image
市場調查報告書

基因治療市場:全球機會分析與產業預測

Gene Therapy Market by Vector Type, Gene Type, and Applications - Global Opportunity Analysis and Industry Forecast, 2017-2023

出版商 Allied Market Research 商品編碼 621933
出版日期 內容資訊 英文 232 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
基因治療市場:全球機會分析與產業預測 Gene Therapy Market by Vector Type, Gene Type, and Applications - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日期: 2018年02月01日 內容資訊: 英文 232 Pages
簡介

本報告提供全球基因治療市場相關調查,彙整市場概要與成長預測,各分類市場,各地區趨勢,及加入此市場的主要企業的簡介等資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 大企業的定位
  • 波特五力分析
  • 市場趨勢

第4章 媒介類別市場

  • 概要
  • 病毒載體
  • 非病毒載體

第5章 遺傳基因類別市場

  • 概要
  • 抗原
  • 細胞激素
  • 腫瘤抑制劑
  • 自殺
  • 缺乏
  • 生長因子
  • 受體
  • 其他

第6章 各用途市場

  • 概要
  • 腫瘤疾病
  • 罕見疾病
  • 心血管疾病
  • 神經疾病
  • 感染疾病
  • 其他

第7章 各地區市場

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美

第8章 企業簡介

  • Adaptimmune Therapeutics Plc.
  • Biocancell Ltd.
  • Bluebird Bio, Inc.
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Glaxosmithkline Plc
  • Merck & Co., Inc.
  • Novartis AG
  • Oncogenex Pharmaceuticals, Inc.
  • Spark Therapeutics, Inc.

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: LI 182841

The global gene therapy market was valued at $584 million in 2016, and is estimated to reach $4,402 million by 2023, registering a CAGR of 33.3% from 2017 to 2023. Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patients cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation. The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools. For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment. Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy.

The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market.

The global gene therapy market is segmented based on vector type, gene type, application, and geography. Based on vector type, it is categorized into viral vector and non-viral vector. Viral vector is further segmented into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Non-viral vector is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. Based on gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. Based on application, the market is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS

  • This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
  • The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
  • In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Vector Type

  • Viral vector
  • Retroviruses
  • Lentiviruses
  • Adenoviruses
  • Adeno Associated Virus
  • Herpes Simplex Virus
  • Poxvirus
  • Vaccinia Virus
  • Others
  • Non-viral vector
  • Naked/Plasmid Vectors
  • Gene Gun
  • Electroporation
  • Lipofection
  • Others

By Gene Type

  • Antigen
  • Cytokine
  • Tumor Suppressor
  • Suicide
  • Deficiency
  • Growth factors
  • Receptors
  • Others

By Application

  • Oncological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious disease
  • Other Diseases

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Republic of South Africa
  • Rest of LAMEA

KEY PLAYERS PROFILED

  • Novartis
  • Kite Pharma, Inc.
  • GlaxoSmithKline PLC
  • Spark Therapeutics Inc.
  • Bluebird bio Inc.
  • Genethon
  • Transgene SA
  • Applied Genetic Technologies Corporation
  • Oxford BioMedica
  • NewLink Genetics Corp.

The other players of the gene therapy market include (companies not profiled in the report):

  • Amgen
  • Epeius Biotechnologies
  • Abeona Therapeutics
  • Sanofi
  • UniQure
  • Juno Therapeutics
  • Adaptimmune
  • Celgene
  • Advantagene

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Key market segments
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
      • 3.2.2.1. Top winning strategies, by year, 2015-2017*
      • 3.2.2.2. Top winning strategies, by development, 2015-2017* (%)
      • 3.2.2.3. Top winning strategies, by company, 2015-2017*
  • 3.3. Top player positioning, 2016
  • 3.4. Porters five forces analysis
  • 3.5. Market dynamics
    • 3.5.1. Drivers
      • 3.5.1.1. High investment for R&D activities pertaining to gene therapy
      • 3.5.1.2. Increase in prevalence of cancer
      • 3.5.1.3. Growth in awareness regarding gene therapy
    • 3.5.2. Restraints
      • 3.5.2.1. High cost associated with gene therapies
      • 3.5.2.2. Unwanted immune responses
    • 3.5.3. Opportunity
      • 3.5.3.1. Untapped potential for emerging markets

CHAPTER 4: GENE THERAPY MARKET, BY VECTOR TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Viral vectors
    • 4.2.1. Key market trends
    • 4.2.2. Key growth factors and opportunities
    • 4.2.3. Market size and forecast
    • 4.2.4. Market Analysis by country
    • 4.2.5. Adenovirus
    • 4.2.6. Lentivirus
    • 4.2.7. Retrovirus
    • 4.2.8. Adeno-associated virus
    • 4.2.9. Herpes simplex virus
    • 4.2.10. Poxvirus
    • 4.2.11. Vaccinia virus
    • 4.2.12. Others
  • 4.3. Nonviral techniques
    • 4.3.1. Key market trends
    • 4.3.2. Key growth factors and opportunities
    • 4.3.3. Market size and forecast
    • 4.3.4. Market Analysis by country
    • 4.3.5. Naked plasmid vector
    • 4.3.6. Gene gun
    • 4.3.7. Electroporation
    • 4.3.8. Lipofection
    • 4.3.9. Others

CHAPTER 5: GENE THERAPY MARKET, BY GENE TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Antigen
    • 5.2.1. Market size and forecast
    • 5.2.2. Market size and forecast by country
  • 5.3. Cytokine
    • 5.3.1. Market size and forecast
    • 5.3.2. Market Analysis, by country
  • 5.4. Tumor suppressor
    • 5.4.1. Market size and forecast
    • 5.4.2. Market Analysis, by country
  • 5.5. Suicide
    • 5.5.1. Market size and forecast
    • 5.5.2. Market Analysis, by country
  • 5.6. Deficiency
    • 5.6.1. Market size and forecast
    • 5.6.2. Market Analysis, by country
  • 5.7. Growth factors
    • 5.7.1. Market size and forecast
    • 5.7.2. Market Analysis, by country
  • 5.8. Receptors
    • 5.8.1. Market size and forecast
    • 5.8.2. Market Analysis, by country
  • 5.9. Others
    • 5.9.1. Market size and forecast
    • 5.9.2. Market Analysis, by country

CHAPTER 6: GENE THERAPY MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Oncological disorders
    • 6.2.1. Market size and forecast
    • 6.2.2. Market Analysis, by country
  • 6.3. Rare diseases
    • 6.3.1. Market size and forecast
    • 6.3.2. Market Analysis, by country
  • 6.4. Cardiovascular diseases
    • 6.4.1. Market size and forecast
    • 6.4.2. Market Analysis, by country
  • 6.5. Neurological disorders
    • 6.5.1. Market size and forecast
    • 6.5.2. Market Analysis, by country
  • 6.6. Infectious diseases
    • 6.6.1. Market size and forecast
    • 6.6.2. Market Analysis, by country
  • 6.7. Other diseases
    • 6.7.1. Market size and forecast
    • 6.7.2. Market Analysis, by country

CHAPTER 7: GENE THERAPY MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. North America
    • 7.2.1. Key market trends
    • 7.2.2. Key growth factors and opportunities
    • 7.2.3. Market size and forecast, by country
    • 7.2.4. Market size and forecast, by vector type
    • 7.2.5. Market size and forecast, by gene type
    • 7.2.6. Market size and forecast, by application
      • 7.2.6.1. U.S. market size and forecast, by vector type
      • 7.2.6.2. U.S. market size and forecast, by gene type
      • 7.2.6.3. U.S. market size and forecast, by application
      • 7.2.6.4. Canada market size and forecast, by vector type
      • 7.2.6.5. Canada market size and forecast, by gene type
      • 7.2.6.6. Canada market size and forecast, by application
      • 7.2.6.7. Mexico market size and forecast, by vector type
      • 7.2.6.8. Mexico market size and forecast, by gene type
      • 7.2.6.9. Mexico market size and forecast, by application
  • 7.3. Europe
    • 7.3.1. Key market trends
    • 7.3.2. Key growth factors and opportunities
    • 7.3.3. Market size and forecast, by country
    • 7.3.4. Market size and forecast, by vector type
    • 7.3.5. Market size and forecast, by gene type
    • 7.3.6. Market size and forecast, by application
      • 7.3.6.1. Germany market size and forecast, by vector type
      • 7.3.6.2. Germany market size and forecast, by gene type
      • 7.3.6.3. Germany market size and forecast, by application
      • 7.3.6.4. France market size and forecast, by vector type
      • 7.3.6.5. France market size and forecast, by gene type
      • 7.3.6.6. France market size and forecast, by application
      • 7.3.6.7. UK market size and forecast, by vector type
      • 7.3.6.8. UK market size and forecast, by gene type
      • 7.3.6.9. UK market size and forecast, by application
      • 7.3.6.10. Italy market size and forecast, by vector type
      • 7.3.6.11. Italy market size and forecast, by gene type
      • 7.3.6.12. Italy market size and forecast, by application
      • 7.3.6.13. Spain market size and forecast, by vector type
      • 7.3.6.14. Spain market size and forecast, by gene type
      • 7.3.6.15. Spain market size and forecast, by application
      • 7.3.6.16. Rest of Europe market size and forecast, by vector type
      • 7.3.6.17. Rest of Europe market size and forecast, by gene type
      • 7.3.6.18. Rest of Europe market size and forecast, by application
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends
    • 7.4.2. Key growth factors and opportunities
    • 7.4.3. Market size and forecast, by country
    • 7.4.4. Market size and forecast, by vector type
    • 7.4.5. Market size and forecast, by gene type
    • 7.4.6. Market size and forecast, by application
      • 7.4.6.1. Japan market size and forecast, by vector type
      • 7.4.6.2. Japan market size and forecast, by gene type
      • 7.4.6.3. Japan market size and forecast, by application
      • 7.4.6.4. China market size and forecast, by vector type
      • 7.4.6.5. China market size and forecast, by gene type
      • 7.4.6.6. China market size and forecast, by application
      • 7.4.6.7. India market size and forecast, by vector type
      • 7.4.6.8. India market size and forecast, by gene type
      • 7.4.6.9. India market size and forecast, by application
      • 7.4.6.10. South Korea market size and forecast, by vector type
      • 7.4.6.11. South Korea market size and forecast, by gene type
      • 7.4.6.12. South Korea market size and forecast, by application
      • 7.4.6.13. Rest of Asia-Pacific market size and forecast, by vector type
      • 7.4.6.14. Rest of Asia-Pacific market size and forecast, by gene type
      • 7.4.6.15. Rest of Asia-Pacific market size and forecast, by application
  • 7.5. LAMEA
    • 7.5.1. Key market trends
    • 7.5.2. Key growth factors and opportunities
    • 7.5.3. Market size and forecast, by country
    • 7.5.4. Market size and forecast, by vector type
    • 7.5.5. Market size and forecast, by gene type
    • 7.5.6. Market size and forecast, by application
      • 7.5.6.1. Brazil market size and forecast, by vector type
      • 7.5.6.2. Brazil market size and forecast, by gene type
      • 7.5.6.3. Brazil market size and forecast, by application
      • 7.5.6.4. South Africa market size and forecast, by vector type
      • 7.5.6.5. South Africa market size and forecast, by gene type
      • 7.5.6.6. South Africa market size and forecast, by application
      • 7.5.6.7. Rest of LAMEA market size and forecast, by vector type
      • 7.5.6.8. Rest of LAMEA market size and forecast, by gene type
      • 7.5.6.9. Rest of LAMEA market size and forecast, by application

CHAPTER 8: COMPANY PROFILE

  • 8.1. Adaptimmune Therapeutics Plc.
    • 8.1.1. Company overview
    • 8.1.2. Company snapshot
    • 8.1.3. Operating business segments
    • 8.1.4. Product portfolio
    • 8.1.5. Business performance
    • 8.1.6. Key strategic moves and developments
  • 8.2. Biocancell Ltd.
    • 8.2.1. Company overview
    • 8.2.2. Company snapshot
    • 8.2.3. Operating business segments
    • 8.2.4. Product portfolio
  • 8.3. Bluebird Bio, Inc.
    • 8.3.1. Company overview
    • 8.3.2. Company snapshot
    • 8.3.3. Operating business segments
    • 8.3.4. Business performance
    • 8.3.5. Key strategic moves and developments
  • 8.4. Celgene Corporation
    • 8.4.1. Company overview
    • 8.4.2. Company snapshot
    • 8.4.3. Operating business segments
    • 8.4.4. Business performance
    • 8.4.5. Key strategic moves and developments
  • 8.5. Gilead Sciences, Inc.
    • 8.5.1. Company overview
    • 8.5.2. Company snapshot
    • 8.5.3. Operating business segments
    • 8.5.4. Product portfolio
    • 8.5.5. Business performance
    • 8.5.6. Key strategic moves and developments
  • 8.6. Glaxosmithkline Plc
    • 8.6.1. Company overview
    • 8.6.2. Company snapshot
    • 8.6.3. Operating business segments
    • 8.6.4. Product portfolio
    • 8.6.5. Business performance
    • 8.6.6. Key strategic moves and developments
  • 8.7. Merck & Co., Inc.
    • 8.7.1. Company overview
    • 8.7.2. Company snapshot
    • 8.7.3. Operating business segments
    • 8.7.4. Product portfolio
    • 8.7.5. Business performance
    • 8.7.6. Key strategic moves and developments
  • 8.8. Novartis AG
    • 8.8.1. Company overview
    • 8.8.2. Company snapshot
    • 8.8.3. Operating business segments
    • 8.8.4. Product portfolio
    • 8.8.5. Business performance
    • 8.8.6. Key strategic moves and developments
  • 8.9. Oncogenex Pharmaceuticals, Inc.
    • 8.9.1. Company overview
    • 8.9.2. Company snapshot
    • 8.9.3. Operating business segments
    • 8.9.4. Business performance
    • 8.9.5. Key strategic moves and developments
  • 8.10. Spark Therapeutics, Inc.
    • 8.10.1. Company overview
    • 8.10.2. Company snapshot
    • 8.10.3. Operating business segments
    • 8.10.4. Product portfolio
    • 8.10.5. Business performance
    • 8.10.6. Key strategic moves and developments

List of Tables

  • TABLE 01. GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 02. GLOBAL GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 03. GLOBAL GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 04. GENE THERAPY MARKET FOR NONVIRAL VECTORS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 05. GLOBAL GENE THERAPY MARKET FOR NONVIRAL VECTORS, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 06. GLOBAL GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 07. ANTIGEN GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 08. CYTOKINE GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 09. TUMOR SUPPRESSOR GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 10. SUICIDE GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 11. DEFICIENCY GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 12. GROWTH FACTORS GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 13. RECEPTORS GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 14. GENE THERAPY MARKET FOR OTHER GENE TYPE, BY REGION, 2016-2023 ($MILLION)
  • TABLE 15. GLOBAL GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 16. GENE THERAPY MARKET FOR ONCOLOGICAL DISORDERS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 17. GENE THERAPY MARKET FOR RARE DISEASES, BY REGION, 2016-2023 ($MILLION)
  • TABLE 18. GENE THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2016-2023 ($MILLION)
  • TABLE 19. GENE THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 20. GENE THERAPY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2016-2023 ($MILLION)
  • TABLE 21. GENE THERAPY MARKET FOR OTHER DISEASES, BY REGION, 2016-2023 ($MILLION)
  • TABLE 22. GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 23. NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 24. NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 25. NORTH AMERICA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 26. NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 27. U.S. GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 28. U.S. GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 29. U.S. GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 30. CANADA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 31. CANADA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 32. CANADA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 33. MEXICO GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 34. MEXICO GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 35. MEXICO GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 36. EUROPE GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 37. EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 38. EUROPE GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 39. EUROPE GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 40. GERMANY GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 41. GERMANY GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 42. GERMANY GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 43. FRANCE GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 44. FRANCE GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 45. FRANCE GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 46. UK GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 47. UK GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 48. UK GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 49. ITALY GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 50. ITALY GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 51. ITALY GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 52. SPAIN GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 53. SPAIN GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 54. SPAIN GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 55. REST OF EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 56. REST OF EUROPE GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 57. REST OF EUROPE GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 58. ASIA-PACIFIC GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 59. ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 60. ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 61. ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 62. JAPAN GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 63. JAPAN GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 64. JAPAN GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 65. CHINA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 66. CHINA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 67. CHINA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 68. INDIA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 69. INDIA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 70. INDIA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 71. SOUTH KOREA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 72. SOUTH KOREA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 73. SOUTH KOREA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 74. REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 75. REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 76. REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 77. LAMEA GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 78. LAMEA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 79. LAMEA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 80. LAMEA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 81. BRAZIL GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 82. BRAZIL GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 83. BRAZIL GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 84. SOUTH AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 85. SOUTH AFRICA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 86. SOUTH AFRICA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 87. REST OF LAMEA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
  • TABLE 88. REST OF LAMEA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
  • TABLE 89. REST OF LAMEA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
  • TABLE 90. ADAPTIMMUNE THERAPEUTICS PLC.: COMPANY SNAPSHOT
  • TABLE 91. ADAPTIMMUNE THERAPEUTICS PLC.: BUSINESS UNIT
  • TABLE 92. ADAPTIMMUNE THERAPEUTICS PLC.: PRODUCT PORTFOLIO
  • TABLE 93. BIOCANCELL LTD.: COMPANY SNAPSHOT
  • TABLE 94. BIOCANCELL LTD.: PRODUCT CATEGORY
  • TABLE 95. BIOCANCELL LTD.: PRODUCT PORTFOLIO
  • TABLE 96. BLUEBIRD BIO, INC.: COMPANY SNAPSHOT
  • TABLE 97. BLUEBIRD BIO, INC.: PRODUCT CATEGORY
  • TABLE 98. CELGENE CORPORATION: COMPANY SNAPSHOT
  • TABLE 99. CELGENE CORPORATION: OPERATING SEGMENTS
  • TABLE 100. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 101. GILEAD SCIENCES, INC.: OPERATING SEGMENTS
  • TABLE 102. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 103. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 104. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 105. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 106. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 107. MERCK & CO., INC.: OPERATING SEGMENTS
  • TABLE 108. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 109. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 110. NOVARTIS AG : OPERATING DIVISION
  • TABLE 111. NOVARTIS AG : PRODUCT PORTFOLIO
  • TABLE 112. ONCOGENEX PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 113. ONCOGENEX PHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 114. SPARK THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 115. SPARK THERAPEUTICS, INC.: PRODUCT CATEGORY
  • TABLE 116. SPARK THERAPEUTICS, INC.: PRODUCT PORTFOLIO

List of Figures

  • FIGURE 01. GLOBAL GENE THERAPY MARKET SEGMENTATION
  • FIGURE 02. TOP INVESTMENT POCKETS: BY GENE TYPE, 2016
  • FIGURE 03. TOP PLAYER POSITIONING, 2016
  • FIGURE 04. BARGAINING POWER OF BUYERS
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. THREAT OF NEW ENTRANTS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. COMPETITIVE RIVALRY
  • FIGURE 09. RESTRAINTS AND DRIVERS: GLOBAL GENE THERAPY MARKET
  • FIGURE 10. COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR VIRAL VECTORS, 2016 & 2023 ($MILLION)
  • FIGURE 11. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR NON-VIRAL VECTORS, 2016 & 2023 (%)
  • FIGURE 12. COMPARATIVE REGIONAL ANALYSIS OF ANTIGEN GENE THERAPY MARKET, 2016 & 2023 (%)
  • FIGURE 13. COMPARATIVE REGIONAL ANALYSIS OF CYTOKINE GENE THERAPY MARKET, 2016 & 2023 (%)
  • FIGURE 14. COMPARATIVE REGIONAL ANALYSIS OF TUMOR SUPPRESSOR GENE THERAPY MARKET, 2016 & 2023 (%)
  • FIGURE 15. COMPARATIVE REGIONAL ANALYSIS OF SUICIDE GENE THERAPY MARKET, 2016 & 2023 (%)
  • FIGURE 16. COMPARATIVE REGIONAL ANALYSIS OF DEFICIENCY GENE THERAPY MARKET, 2016 & 2023 (%)
  • FIGURE 17. COMPARATIVE REGIONAL ANALYSIS OF GROWTH FACTORS GENE THERAPY MARKET, 2016 & 2023 (%)
  • FIGURE 18. COMPARATIVE REGIONAL ANALYSIS OF RECEPTORS GENE THERAPY MARKET, 2016 & 2023 (%)
  • FIGURE 19. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR OTHER GENE TYPE, 2016 & 2023 (%)
  • FIGURE 20. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR ONCOLOGICAL DISORDERS, 2016 & 2023 (%)
  • FIGURE 21. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR RARE DISEASES, 2016 & 2023 (%)
  • FIGURE 22. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR CARDIOVASCULAR DISEASES, 2016 & 2023 (%)
  • FIGURE 23. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR NEUROLOGICAL DISORDERS, 2016 & 2023 (%)
  • FIGURE 24. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR INFECTIOUS DISEASES, 2016 & 2023 (%)
  • FIGURE 25. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR OTHER DISEASES, 2016 & 2023 (%)
  • FIGURE 26. ADAPTIMMUNE THERAPEUTICS PLC.: REVENUE, 2014-2016 ($MILLION)
  • FIGURE 27. BLUEBIRD BIO, INC.: REVENUE, 2014-2016 ($MILLION)
  • FIGURE 28. CELGENE CORPORATION: REVENUE, 2014-2016 ($MILLION)
  • FIGURE 29. CELGENE CORPORATION: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 30. CELGENE CORPORATION: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 31. GILEAD SCIENCES, INC.: REVENUE, 2014-2016 ($MILLION)
  • FIGURE 32. GILEAD SCIENCES, INC.: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 33. GLAXOSMITHKLINE PLC.: REVENUE, 2014-2016 ($MILLION)
  • FIGURE 34. GLAXOSMITHKLINE PLC.: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 35. GLAXOSMITHKLINE PLC.: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 36. MERCK & CO., INC.: REVENUE, 2014-2016 ($MILLION)
  • FIGURE 37. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2016 (%)
  • FIGURE 38. MERCK & CO., INC.: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
  • FIGURE 39. NOVARTIS AG: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 40. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2017 (%)
  • FIGURE 41. NOVARTIS AG: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 42. ONCOGENEX PHARMACEUTICALS, INC.: REVENUE, 2014-2016 ($MILLION)
  • FIGURE 43. SPARK THERAPEUTICS, INC.: REVENUE, 2014-2016 ($MILLION)
Back to Top